Prevalence of NUT carcinoma in head and neck: Analysis of 362 cases with literature review

Lee, Taebum; Cho, Junhun; Baek, Chung‐Hwan; Son, Young‐Ik; Jeong, Han‐Sin; Chung, Man Ki; Hong, Sang Duk; Ahn, Yong Chan; Oh, Doo‐Yi; Noh, Jae Myoung; Park, Keunchil; Ahn, Myung‐Ju; Kim, Hyungjin; Kim, Yi Kyung; Ko, Young Hyeh

doi:10.1002/hed.26067

Cited by 27 publications

(35 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NUT-C is considered a very rare entity, but the true prevalence in the head and neck is indeed unknown. Recently, Lee et al [7] reported that NUT-C accounts for 2.9% and 12.5% of poorly or undifferentiated carcinomas arising in the head and neck and sinonasal tract, respectively. Furthermore, the authors confirmed that the sinonasal tract represents the most common initial presenting site of the head and neck (73.4%), followed by the salivary glands (11%), larynx (7.3%), pharynx (4.6%), and oral cavity (3.7%).…”

Section: Epidemiologymentioning

confidence: 99%

Sinonasal NUT Carcinoma: Delayed Diagnosis Due to the COVID-19 Pandemic and a Review of the Literature

Crocetta

Botti

Fornaciari

et al. 2021

Head and Neck Pathol

View full text Add to dashboard Cite

NUT carcinoma (NUT-C) is a relatively new malignancy that was recently listed in the 4th edition of the WHO Classification of Head and Neck Tumors in 2017. NUT carcinoma is a rare, aggressive, poorly differentiated carcinoma genetically defined by chromosomal rearrangement of the nuclear protein in testis (NUTM1) gene. The prognosis is extremely poor, with a mean survival < 1 year. Recent publications suggest a multimodality treatment approach. In the existing literature, only a few reports of sinonasal NUT-C have been reported. Sinonasal NUT-C is considered a very rare entity, but because of its recent inclusion as a head and neck malignancy, its true prevalence is unknown. We report the case of a 56-year-old woman with NUT-C of the sinonasal cavities. In the case reported, the coexistence of Coronavirus disease 2019 (COVID-19)-related nasal congestion delayed the diagnosis of NUT-C. Clinical presentation, diagnosis and treatment modalities are discussed together with a review of the literature.

show abstract

Section: Epidemiologymentioning

confidence: 99%

Sinonasal NUT Carcinoma: Delayed Diagnosis Due to the COVID-19 Pandemic and a Review of the Literature

Crocetta

Botti

Fornaciari

et al. 2021

Head and Neck Pathol

View full text Add to dashboard Cite

show abstract

“…IHC slides were interpreted by two independent pathologists (YAC and JHH) as previously described. 13 Antibody against anaplastic lymphoma kinase (ALK) (clone 5A4; 1:30, Novocastra, Newcastle upon Tyne, UK) was used and evaluation of ALK IHC expression was done as previously described. 18 PD-L1 expression was evaluated using PD-L1 IHC 22C3 pharmDx assay (Dako, Glostrup, Denmark) as previously described.…”

Section: Immunohistochemical Staining Interpretation and Fluorescence In Situ Hybridization Assaymentioning

confidence: 99%

“…15,16 Approximately 70% of NUT carcinoma cases are associated with BRD4-NUT fusion and in the remaining 30%, NUT has been previously reported to fuse with BRD3 or other unknown genes. 13,17 In this study, we retrospectively analyzed patients with pulmonary NUT carcinoma diagnosed by NUT immunohistochemical staining and discuss the differential diagnosis to provide information for this rare and aggressive entity.…”

Section: Introductionmentioning

confidence: 99%

“…Previous studies have suggested a bromodomain inhibitor can be used as a target inhibitor of BRD ‐ NUT fusion 15,16 . Approximately 70% of NUT carcinoma cases are associated with BRD4 ‐ NUT fusion and in the remaining 30%, NUT has been previously reported to fuse with BRD3 or other unknown genes 13,17 …”

Section: Introductionmentioning

confidence: 99%

“…7 As a result, it is often misdiagnosed as poorly differentiated carcinoma or undifferentiated carcinoma if NUT is not suspected. 5,7,12,13 A diagnosis of NUT carcinoma can be made using immunohistochemical staining for NUT protein, which shows 99% negative predictive value and a positive predictive value of 100%. 9,14 Previous studies have suggested a bromodomain inhibitor can be used as a target inhibitor of BRD-NUT fusion.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clinicopathological characteristics of primary lung nuclear protein in testis carcinoma: A single‐institute experience of 10 cases

et al. 2020

View full text Add to dashboard Cite

Background Nuclear protein in testis (NUT) carcinoma is a rare tumor associated with NUT rearrangement that can present as poorly differentiated to undifferentiated carcinoma, with or without abrupt squamous differentiation. It is often misdiagnosed as poorly differentiated carcinoma or undifferentiated carcinoma if NUT is not suspected. In this study, we retrospectively analyzed pulmonary NUT carcinoma cases diagnosed with NUT immunohistochemical staining and discuss the differential diagnosis to provide information for this rare and aggressive entity. Methods Cases, diagnosed as “NUT carcinoma” in lung pleura and “metastatic NUT carcinoma from the lung” in lymph nodes were diagnosed between 2017 and 2019 at the Samsung Medical Center (SMC). Clinical features such as age, sex, treatment and follow‐up period, and pathological reports were obtained by reviewing patients’ electronic medical records. Results A total of 10 NUT carcinoma cases were found in the SMC pathology database. Seven patients were men and six were non‐smokers. Tumor cells showed various cellular features such as round, squamoid, and spindle. Some cases had initially been misdiagnosed as spindle cell neoplasm, round cell sarcoma, squamous cell carcinoma and small cell carcinoma. All cases showed diffuse strong nuclear expression of NUT immunohistochemical staining, and some were positive for p63 staining and negative for CD56 staining. Conclusions NUT carcinoma is often misdiagnosed because of its various morphologies. It is important to consider NUT as one of the differential diagnoses when encountering lung biopsy with undifferentiated morphology. Key points Due to various morphological features, NUT carcinoma can be misdiagnosed It is important to consider NUT carcinoma when diagnosing a poorly differentiated or undifferentiated tumor

show abstract

Sinonasal NUT carcinoma: A consecutive case series and systematic review

Ramesh,

Contrera,

Shakibai

et al. 2023

Head & Neck

View full text Add to dashboard Cite

BackgroundSinonasal NUT carcinoma is an extremely rare, lethal malignancy with limited literature.MethodsA case series was conduction of all patients with sinonasal NUT carcinoma at a single institution between 2010 and 2022. Survival and associated were evaluated. A systematic review of the literature was performed.ResultsIn 12 patients, followed for a median of 1.5 years, the median overall survival (OS) and disease‐specific survival (DSS) were both 14.6 months. Patients with maxillary sinus tumors were 91% more likely to survive (hazard ratio [HR]: 0.094, 95% confidence interval [CI]: 0.011–0.78, p = 0.011). Patients with higher‐stage disease stage had worse OS (stage IVb‐c vs. III‐IVa, p = 0.05). All three patients who were alive with no evidence of disease received induction chemotherapy.ConclusionFor patients with sinonasal NUT carcinoma, the median survival was 15 months but better with lower‐stage and maxillary tumors. Induction chemotherapy may be beneficial.

show abstract

Prevalence of NUT carcinoma in head and neck: Analysis of 362 cases with literature review

Cited by 27 publications

References 48 publications

Sinonasal NUT Carcinoma: Delayed Diagnosis Due to the COVID-19 Pandemic and a Review of the Literature

Sinonasal NUT Carcinoma: Delayed Diagnosis Due to the COVID-19 Pandemic and a Review of the Literature

Clinicopathological characteristics of primary lung nuclear protein in testis carcinoma: A single‐institute experience of 10 cases

Sinonasal NUT carcinoma: A consecutive case series and systematic review

Contact Info

Product

Resources

About